Vascular & Endovascular

This channel includes news on non-coronary vascular disease and therapies. These include peripheral artery disease (PAD), abdominal and thoracic aortic aneurysm (AAA and TAA), aortic dissection, pulmonary embolism (PE), critical limb ischemia (CLI), carotid artery and stroke interventions, venous interventions, deep vein thrombosis (DVT), and interventional radiology therapies. The focus on most of these therapies is minimally invasive, catheter-based procedures performed in a cath lab.

Thumbnail

AHA.14: Here's the buzz on second-hand smoke from pot

According to findings presented Nov. 16 at the American Heart Association scientific session in Chicago, endothelial function was just as impaired in rats exposed to second-hand smoke from marijuana as cigarettes.

Silk Road Medical announces 30 day results in the Roadster clinical trial for carotid artery revascularization

Sunnyvale, CA. -- Silk Road Medical, Inc. announced the 30 day outcomes from the ROADSTER IDE Study at the VIVA 2014 Vascular Interventional Advances Annual Conference in Las Vegas, Nevada. The trial studied the treatment of carotid artery stenosis with a new device and hybrid procedure combining the best elements of carotid endarterectomy (CEA) and carotid artery stenting (CAS).

Thumbnail

VIVA.14: Promising 1-year results for drug-coated balloons in diabetics

Patients with peripheral artery disease (PAD) and diabetes who underwent treatment with a drug-coated balloon fared better than counterparts who received standard care, according to a subanalysis of the IN.PACT SFA trial.

VIVA.14: Zilver PTX holds strong at five years

At five years, the Zilver PTX stent proved to be a durable treatment for peripheral artery disease with sustained benefit, results presented Nov. 4 at the 2014 Vascular Interventional Advances (VIVA) meeting showed.

Thumbnail

VIVA.14: DISRUPT PAD brings lithoplasty technique to peripheral lesions

Shockwaves appear to have early success in breaking up calcified lesions safely. In research presented Nov. 5 at the 2014 Vascular Interventional Advances (VIVA) meeting in Las Vegas, a lithotripsy-with-balloon technique used on peripheral artery lesions resulted in all patients achieving less than 50 percent stenosis. 

Covidien announces 12-month DEFINITIVE AR results at VIVA 2014

Covidien announced 12-month results of the DEFINITIVE AR study, the first randomized study designed to identify the clinical benefits of plaque removal using directional atherectomy followed by drug coated balloon. The results were presented by Professor Thomas Zeller of the Universitaets-Herzzentrum, Bad Krozingen, Germany at the Vascular Interventional Advances (VIVA) 2014 conference in Las Vegas, Nev.

Cardinal Health MynxGrip Vascular Closure Device receives Food and Drug Administration approval for venous indication

Cardinal Health today announced that its MynxGrip® Vascular Closure Device recently received Food and Drug Administration approval for use to close femoral veins. The MynxGrip device is now indicated for use to seal 5F, 6F and 7F femoral arterial and femoral venous access sites.

Covidien’s HawkOne Directional Atherectomy System receives FDA 510(K) clearance for the treatment of peripheral arterial disease

Covidien plc (NYSE: COV) today announced U.S. Food and Drug Administration 510(k) clearance for the HawkOne™ directional atherectomy system. The latest addition to Covidien’s directional atherectomy portfolio, the HawkOne system provides physicians with an enhanced cutting mechanism to more effectively treat the widest variety of plaque in patients with peripheral arterial disease (PAD).

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.